Clinical Trials match your criteria
-
Nirogacestat in Ovarian Granulosa Cell Tumors
A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors
-
A Phase 3 Trial of Fianlimab (REGN3767, Anti-Lag-3)+ Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma.
A Phase 3 Trial of Fianlimab (REGN3767, Anti-Lag-3)+ Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma.
-
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
-
Clinical and Histological Outcomes of Patients with Barrett’s Esophagus Undergoing Endoscopic Submucosal Dissection
Clinical and Histological Outcomes of Patients with Barrett's Esophagus Undergoing Endoscopic Submucosal Dissection
-
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
-
Low Rates of Malseating of Modular Dual Mobility Liners but Remain an Issue in Total Hip Arthroplasty
Low Rates of Malseating of Modular Dual Mobility Liners but Remain an Issue in Total Hip Arthroplasty
-
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
-
Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)
A Phase 1b Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
-
Nivo Recurrent Rare CNS Cancer
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers
-
RANDOMIZED TRIAL COMPARING ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY AND SURGICAL GASTROJEJUNOSTOMY IN GASTRIC OUTLET OBSTRUCTION
RANDOMIZED TRIAL COMPARING ENDOSCOPIC ULTRASOUND-GUIDED GASTROJEJUNOSTOMY AND SURGICAL GASTROJEJUNOSTOMY IN GASTRIC OUTLET OBSTRUCTION
